Redx Pharma plc Share Purchases by Directors (6582J)
23 December 2020 - 8:00PM
UK Regulatory
TIDMREDX
RNS Number : 6582J
Redx Pharma plc
23 December 2020
REDX PHARMA PLC
("Redx" or "the Company")
Share Purchases by Directors
Alderley Park, 23 December 2020 - Redx Pharma (AIM:REDX), the
drug discovery and development Group focused on cancer and
fibrosis, announces that it has been notified that Lisa Anson,
Chief Executive Officer, has on Tuesday 22 December acquired 39,998
Redx ordinary shares at the following prices:
Number of Ordinary shares purchased Price per share (pence)
39,998 50p
------------------------
Following this, Mrs Anson will hold 129,284 ordinary shares in
the Company, representing 0.05 per cent. of the issued share
capital.
-Ends-
For further information, please contact:
Redx Pharma Plc T: +44 1625 469
918
Lisa Anson, Chief Executive Officer
James Mead, Chief Financial Officer
SPARK Advisory Partners (Nominated Advisor) T: +44 203 368
3550
Matt Davis/ Adam Dawes
WG Partners LLP (Broker) T: +44 20 3705
9330
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting T: +44 20 3727
1000
Simon Conway/Ciara Martin
About Redx Pharma Plc
Redx is a UK biotechnology Group whose shares are traded on AIM
(AIM:REDX). Redx is focused on creating and developing first, or
potentially best in class drugs, in specific areas of cancer and
fibrosis that address significant unmet medical need. Redx has an
in-house discovery team with proven world-class chemistry
capabilities.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
---- -----------------------------------------------------------------------
a. Name Lisa Anson
------------------------------------
2 Reason for notification
--------------------------------- ------------------------------------
a. Position/Status Chief Executive
--------------------------------- ------------------------------------
b. Initial notification/ Initial Notification
Amendment
--------------------------------- ------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a. Name Redx Pharma Plc
---------------------------------
b. LEI 213800HMS4EBXO589Y37
--------------------------------- ------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---- -----------------------------------------------------------------------
a. Description of Ordinary Shares of 1p each
the financial
instrument, type
of instrument
ISIN: GB00BSNB6S51
Identification
Code
--------------------------------- ------------------------------------
b. Nature of the Purchase
transaction
--------------------------------- ------------------------------------
c. Price(s) and volume(s) 39,998 at 50 pence per share
--------------------------------- ------------------------------------
d. Aggregated information 39,998 at 50 pence per share
- Aggregated Volume
- Price
--------------------------------- ------------------------------------
e. Date of the transaction 22/12/20
--------------------------------- ------------------------------------
f. Place of the transaction Outside of trading venue
--------------------------------- ------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFIFVTFVLVFII
(END) Dow Jones Newswires
December 23, 2020 04:00 ET (09:00 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024